株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CAR-T治療薬市場の分析・予測

CAR-T Therapies Market (2nd Edition), 2019-2030

発行 ROOTS ANALYSIS 商品コード 665456
出版日 ページ情報 英文 580 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。
CAR-T治療薬市場の分析・予測 CAR-T Therapies Market (2nd Edition), 2019-2030
出版日: 2019年08月31日 ページ情報: 英文 580 Pages
概要

当レポートでは、CAR-T治療薬の市場を調査し、癌治療・癌免疫治療・T細胞免疫療法の概要、キメラ抗原受容体発現T細胞 (CAR-T) 療法の概要、CAR-T治療薬の臨床試験の動向、上市済み製品・開発後期製品のプロファイル、疾患区分別の分析、新技術の動向、細胞治療薬製造のケーススタディ、市場規模・市場機会の分析、主要企業のプロファイル、将来の展望などをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 本章の概要
  • 癌治療の柱
  • 免疫療法:新しい治療オプション
  • 癌免疫治療の基礎
  • 癌免疫治療薬の分類
    • 作用機序別
    • 標的タイプ別
    • アプローチ別
    • 製品クラス別
  • T細胞免疫療法の進化
  • T細胞免疫療法に関する考察
  • T細胞リダイレクションのための戦略
  • 組み換えT細胞の製造
  • T細胞形質導入
  • T細胞免疫療法:対象治療領域
  • T細胞免疫療法:主要課題

第4章 キメラ抗原受容体発現T細胞 (CAR-T) 療法

  • 本章の概要
  • 開発の経緯
  • 解剖学的レイアウト
  • CAR-T療法の発展
  • Universal CAR-T
  • 好まれる投薬ルート
  • 毒性の課題
  • 毒性の管理
  • CD19:魅力的標的
  • その他の標的
  • CAR-T療法の課題

第5章 ソーシャルメディア上の新興動向

第6章 市場環境

  • 本章の概要
  • CAR-T療法:パイプラインの概要
  • CAR-T療法:CAR構成の分析

第7章 CAR-T治療薬:主な分析

  • 本章の概要
  • CAR-T治療薬の分析:標的抗原の普及度別
    • 血液癌:一般的標的
      • CD19 CAR-T治療薬:競合環境
      • CD19 CAR-T治療薬:主な候補薬の臨床試験結果
      • BCMA CAR-T治療薬:競合環境
      • BCMA CAR-T治療薬:主な候補薬の臨床試験結果
    • 固形腫瘍:一般的標的
      • Meso CAR-T治療薬:競合環境
      • GD2 CAR-T治療薬:競合環境
  • 臨床試験の動向
  • 臨床試験の概要
    • 開発段階別の分布
    • 閑寂分別の分布
    • 治療薬タイプ別の分布
  • キーオピニオンリーダー

第8章 上市済み・開発後期のCAR-T治療薬プロファイル

  • 本章の概要
  • KymriahR / Tisagenlecleucel / CTL019 (Novartis)
  • YescartaR / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
  • JCAR (Juno Therapeutics)
  • CAR-T Series (Cellular Biomedicine Group)
  • CD19 CAR (タカラバイオ)
  • Dual Targeting CAR-T Cell therapies (Autolus)
  • CAR-TTherapies (Sinobioway Cell Therapy)

第9章 疾患区分別の分析

  • 本章の概要
  • 悪性血液疾患
    • 白血病・リンパ腫
    • 多発性骨髄腫
  • 固形腫瘍
    • 転移性黒色腫
    • 肺癌
    • 膀胱癌
    • 腎臓癌
    • 卵巣癌
    • 乳癌

第10章 新技術

  • 本章の概要
  • ゲノム編集技術
  • T細胞治療薬の設計

第11章 ケーススタディ:細胞治療薬製造

  • 本章の概要
  • イントロダクション
  • 主要課題
  • 現在の動向
  • 製造サイトに関する考察
  • 法規制環境

第12章 T細胞免疫療法:コスト・価格の分析

  • 本章の概要
  • 価格への影響因子
  • 価格モデル
  • 償還に関する考察

第13章 市場規模・市場機会の分析

  • 本章の概要
  • 展望・制約
  • 予測手法
  • 総市場
    • 地域別分布
    • 適応症別分布
  • 対象人口・売上予測:製品別
    • KymriahR (Novartis)
    • YescartaR (Gilead Sciences)
    • bb2121 (Celgene / bluebird bio)
    • MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center)
    • CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)
    • GPC3 CAR-T (Shanghai GeneChem)
    • TBI-1501 (タカラバイオ / Jichi Medical University)
    • JCAR017 (Juno Therapeutics / Celgene)
    • IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
    • PCAR-019 (PersonGen BioTherapeutics)
    • AUTO2 (Autolus)
    • AUTO3 (Autolus)
    • BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital)
    • CD19 CAR-T (The Pregene (ShenZhen) Biotechnology / Henan Cancer Hospital)
    • CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University)
    • LCAR-B38M CAR-T (Nanjing Legend Biotech)
    • CD19 CAR-T (Shanghai Bioray Laboratory)

第14章 販促に関する分析

第15章 企業プロファイル

  • 本章の概要
  • Autolus
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Cell Medica
  • Cellectis
  • Cellular Biomedicine Group
  • Innovative Cellular Therapeutics
  • Kite Pharma
  • Novartis
  • Sinobioway Cell Therapy
  • タカラバイオ
  • ZIOPHARM Oncology

第16章 総論

第17章 インタビュー

第18章 付録1:図表

第19章 付録2:企業・組織リスト

目次

CAR-T cell therapies are based on the principle of harnessing the innate potential of the immune system to selectively target and destroy diseased cells. Encouraging clinical results reported across several completed and ongoing trials, coupled to lucrative financing, have inspired many biopharmaceutical developers and academic research groups to focus their efforts on this relatively novel class of cell-based immunotherapies. With two approved products, namely KYMRIAH® (Novartis) and YESCARTA® (Gilead Sciences), CAR-T cell therapies are presently considered among the most promising anticancer therapeutics available, with potential applications in treating other diseases as well. It is worth highlighting that 66% of the pipeline therapies are presently in the clinical stage.

Over 100 companies and 85 academic / research institutes are actively involved therapy development initiatives in this domain. The ongoing research activity in this domain has led to the discovery of several novel molecular targets, which can be exploited for cell therapy development. Further research and characterization of these targets has significantly strengthened the pipelines of stakeholder entities engaged in this market. Driven by the availability of innovative technology platforms, the CAR-T therapies market is poised for success in the long-run as several therapeutic leads have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

Scope of the Report

The "CAR-T Therapies Market, 2019-2030 (2nd edition) " report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations working in this domain. Amongst other elements, the report features the following:

  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
  • A detailed assessment of the current market landscape of CAR-T cell therapies with respect to type of developer (industry / non-industry), phase of development, target therapeutic indication(s), key target antigen(s), source of T-cells (autologous / allogenic), route of administration, type of therapy (monotherapy / combination therapy) and patient segment (children / adults / seniors).
  • Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan and key clinical trial results.
  • An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector and type of co-stimulatory domain used.
  • A detailed analysis highlighting several key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists / researchers involved in the development of CAR-T cell therapies.
  • An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend of initiation of such studies and distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies, especially in China.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of CAR-T cell therapies, along with profiles of key technology providers. Further, it includes a relative competitiveness analysis of different CAR-T cell therapy-based gene editing platforms, based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
  • An elaborate discussion on various factors that form the basis for pricing of cell therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell therapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-T cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such therapies, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report includes potential sales forecasts of CAR-T cell therapies that are currently marketed or are in late stages of development. Additionally, it provides forecasts for the overall CAR-T cell therapy market, wherein both the current and upcoming opportunity is segmented across [A] target indications (acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, hepatocellular carcinoma and colorectal cancer), [B] important target antigens (CD19, BCMA, GPC3 and EGFR) and [C] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the CAR-T cell therapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of CAR-T cell therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of CAR-T cell therapies, factors supporting the growing popularity of CAR-T cell therapies and the challenges associated with such therapies.

Chapter 4 provides insights on the popularity of CAR-T cell therapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.

Chapter 5 provides information on close to 500 CAR-T cell therapies that are currently approved or are in different stages of development (clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of developer(s), phase of development, target therapeutic area(s) and indication(s), key target antigen(s), source of T-cells (autologous / allogenic), route of administration, type of therapy (monotherapy / combination therapy) and patient segment. Further, the chapter features the most active players (in terms of number of pipeline candidates).

Chapter 6 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T cell therapies in hematological cancer and solid tumor space. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapy, type of binding domain, type of vector and type of co-stimulatory domain.

Chapter 7 presents an analysis of the CAR-T clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend and the distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.

Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan and key clinical trial results.

Chapter 9 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the CAR-T cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 10 provides a list of technology platforms that are either available in the market or are being designed for the development of CAR-T cell therapies. A detailed discussion on innovative technology platforms that are being used for the development of CAR-T cell therapies, along with profiles of key technology providers. Further, it includes a competitiveness analysis of different CAR-T-based gene editing platforms, based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

Chapter 11 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 12 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their CAR-T cell therapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for CAR-T cell therapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 13 features an elaborate discussion on the future commercial opportunity offered by CAR-T cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in different phases of development (phase I/II and above), taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] target indications (acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, hepatocellular carcinoma and colorectal cancer), [B] important target antigens (CD19, BCMA, GPC3 and EGFR) and [C] key geographical regions (North America, Europe and Asia Pacific).

Chapter 14 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 15 includes brief company profiles of the leading players in the CAR-T cell therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T cell therapies, technology portfolio (if available), recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Miguel Forte (Chief Operating Officer, TxCell), Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) and Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing).

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Pillars of Cancer Therapy
  • 3.3. Overview of Immunotherapies
  • 3.4. Fundamentals of Cancer Immunotherapy
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
      • 3.5.1.1. Active Immunotherapy
      • 3.5.1.2. Passive Immunotherapy
    • 3.5.2. By Type of Target
    • 3.5.3. By Approach
      • 3.5.3.1. Activation and Suppression Immunotherapy
    • 3.5.4. By Product Class
      • 3.5.4.1. Monoclonal Antibodies
      • 3.5.4.2. Bispecific Antibodies
      • 3.5.4.3. Cytokines
      • 3.5.4.4. Oncolytic Virus Therapy
      • 3.5.4.5. Therapeutic Cancer Vaccines
      • 3.5.4.6. Cell-based Therapies
  • 3.6. T-Cell Immunotherapies
    • 3.6.1. Historical Evolution
    • 3.6.2. Key Considerations for Developing T-Cell Immunotherapies
    • 3.6.3. Strategies Employed for the Redirection of T-Cells
    • 3.6.4. Manufacturing of Engineered T-Cells
    • 3.6.5. T-Cell Transduction and Transfection Methods
      • 3.6.5.1. Retroviral Vectors
      • 3.6.5.2. Lentiviral Vectors
      • 3.6.5.3. Non-viral Transfection Methods
  • 3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
    • 3.7.1. History of Development
    • 3.7.2. Anatomical Layout of CAR
      • 3.7.2.1. Ectodomain
      • 3.7.2.2. Transmembrane (TM) Domain
      • 3.7.2.3. Endodomain
    • 3.7.3. Development of CAR-T Cells
    • 3.7.4. Universal CAR-T Cells
    • 3.7.5. Route of Administration of CAR-T Cell Therapies
    • 3.7.6. Case Study: CD19 CAR-T Cell Therapies
      • 3.7.6.1. Other Important Biological Targets for CAR Development
    • 3.7.7. Challenges Associated with CAR-T Cell Therapies
      • 3.7.7.1. Competitive Risks
      • 3.7.7.2. Clinical Risks
      • 3.7.7.3. Regulatory Risks
      • 3.7.7.4. Commercial Risks

4. EMERGING TRENDS ON SOCIAL MEDIA

  • 4.1. Chapter Overview
  • 4.2. CAR-T Cell Therapies: Trends on Twitter
    • 4.2.1. Historical Trend in Volume of Tweets
    • 4.2.2. Trending Words / Phrases on Twitter
    • 4.2.3. Most Popular Drugs on Twitter
    • 4.2.4. Most Prolific Authors on Twitter
    • 4.2.5. Most Popular Indications and Target Antigens

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. CAR-T Cell Therapies: Overall Market Overview
    • 5.2.1. Analysis by Type of Developer
    • 5.2.2. Analysis by Phase of Development
    • 5.2.3. Analysis by Popular Target Indications
    • 5.2.4. Analysis by Popular Target Antigens
    • 5.2.5. Analysis by Source of T-Cells
    • 5.2.6. Analysis by Route of Administration
    • 5.2.7. Analysis by Patient Segment
    • 5.2.8. Analysis by Type of Therapy
    • 5.2.9. Key Industry Players: Analysis by Number of Therapies in Development
    • 5.2.10. Key Non-Industry Players: Analysis by Number of Therapies in Development

6. KEY INSIGHTS

  • 6.1. Chapter Overview
  • 6.2. CAR-T Cell Therapies: Competitive Analysis by Popular Target Antigens
    • 6.2.1. Popular Targets Related to Hematological Malignancies
      • 6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Therapies
      • 6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Therapies
      • 6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Therapies
      • 6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Therapies
    • 6.2.2. Popular Targets Related to Solid Tumors
      • 6.2.2.1. Competitive Landscape of Meso CAR-T Cell Therapies
      • 6.2.2.2. Clinical Trial Results of Prominent Meso CAR-T Cell Therapies
      • 6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Therapies
      • 6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Therapies
  • 6.3. CAR-T Cell Therapies: Key Opinion Leaders
    • 6.3.1. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
  • 6.4. CAR-T Cell Therapies: CAR Construct Analysis
    • 6.4.1. Analysis by Generation of CAR
    • 6.4.2. Analysis by Type of scFv Antibody
    • 6.4.3. Analysis by Type of Vector
    • 6.4.4. Analysis by Type of Co-Stimulatory Domain(s)

7. CLINICAL TRIAL ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. CAR-T Cell Therapies: Clinical Trial Analysis
    • 7.2.1. Methodology
    • 7.2.2. Analysis by Trial Registration Year
    • 7.2.3. Geographical Analysis by Number of Registered Trials
    • 7.2.4. Case Study: CAR-T Cell Therapy Market in China
    • 7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China

8. CAR-T CELL THERAPY PROFILES

  • 8.1. Chapter Overview
  • 8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
    • 8.2.1. Therapy Overview
    • 8.2.2. Current Development Status
    • 8.2.3. Key Clinical Trial Results
    • 8.2.4. Dosage Regimen, Price and Manufacturing
  • 8.3. YESCARTA® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
    • 8.3.1. Therapy Overview
    • 8.3.2. Current Development Status
    • 8.3.3. Key Clinical Trial Results
    • 8.3.4. Dosage Regimen, Price and Manufacturing
  • 8.4. JCAR (Juno Therapeutics)
    • 8.4.1. Therapy Overview
    • 8.4.2. Current Development Status
    • 8.4.3. Key Clinical Results
      • 8.4.3.1. JCAR014
      • 8.4.3.2. JCAR017
      • 8.4.3.3. JCAR018
      • 8.4.3.4. JCARH125
    • 8.4.4. Dosage Regimen and Manufacturing
  • 8.5. bb2121 (bluebird bio / Celgene)
    • 8.5.1. Therapy Overview
    • 8.5.2. Current Development Status
    • 8.5.3. Key Clinical Trial Results
    • 8.5.4. Dosage Regimen and Manufacturing
  • 8.6. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen Biotech)
    • 8.6.1. Therapy Overview
    • 8.6.2. Current Development Status
    • 8.6.3. Key Clinical Trial Results
    • 8.6.4. Dosage Regimen and Manufacturing
  • 8.7. CD19 CAR-T Cell Therapy (Takara Bio)
    • 8.7.1. Therapy Overview
    • 8.7.2. Current Development Status
    • 8.7.3. Key Clinical Trial Results
    • 8.7.4. Dosage Regimen and Manufacturing
  • 8.8. Dual Targeting CAR-T Cell therapies (Autolus)
    • 8.8.1. Therapy Overview
    • 8.8.2. Current Development Status
    • 8.8.3. Key Clinical Trial Results
      • 8.8.3.1. AUTO2
      • 8.8.3.2. AUTO3
    • 8.8.4. Dosage Regimen and Manufacturing
  • 8.9. CAR-T Cell Therapies (Sinobioway Cell Therapy)
    • 8.9.1. Therapy Overview
    • 8.9.2. Current Development Status
    • 8.9.3. Dosage Regimen and Manufacturing

9. KEY THERAPEUTIC AREAS FOR CAR-T CELL THERAPIES

  • 9.1. Chapter Overview
  • 9.2. Hematological Malignancies
    • 9.2.1. Leukemia and Lymphoma
      • 9.2.1.1. Leukemia: Introduction and Epidemiology
        • 9.2.1.1.1. Acute Myeloid Leukemia (AML)
        • 9.2.1.1.2. Chronic Myeloid Leukemia (CML)
        • 9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
        • 9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
      • 9.2.1.2. Lymphoma: Introduction and Epidemiology
      • 9.2.1.3. Current Treatment Landscape
        • 9.2.1.3.1. Targeted Therapies
      • 9.2.1.4. CAR-T Cell Therapies and Affiliated Research Landscape
        • 9.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
    • 9.2.2. Multiple Myeloma
      • 9.2.2.1. Introduction and Epidemiology
      • 9.2.2.2. Current Treatment Landscape
      • 9.2.2.3. CAR-T Cell Therapies and Affiliated Research Landscape
  • 9.3. Solid Tumors
    • 9.3.1. Metastatic Melanoma
      • 9.3.1.1. Introduction and Epidemiology
      • 9.3.1.2. Current Treatment Landscape
      • 9.3.1.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.2. Lung Cancer
      • 9.3.2.1. Introduction and Epidemiology
      • 9.3.2.2. Current Treatment Landscape
      • 9.3.2.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.3. Pancreatic Cancer
      • 9.3.3.1. Introduction and Epidemiology
      • 9.3.3.2. Current Treatment Landscape
      • 9.3.3.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.4. Liver Cancer
      • 9.3.4.1. Current Treatment Landscape
      • 9.3.4.2. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.5. Breast Cancer
      • 9.3.5.1. Introduction and Epidemiology
      • 9.3.5.2. Current Treatment Landscape
      • 9.3.5.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.6. Ovarian Cancer
      • 9.3.6.1. Introduction and Epidemiology
      • 9.3.6.2. Current Treatment Landscape
      • 9.3.6.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.7. Bladder Cancer
      • 9.3.7.1. Introduction and Epidemiology
      • 9.3.7.2. Current Treatment Landscape
      • 9.3.7.3. CAR-T Cell Therapies and Affiliated Research Landscape
    • 9.3.8. Kidney Cancer
      • 9.3.8.1. Introduction and Epidemiology
      • 9.3.8.2. Current Treatment Landscape
      • 9.3.8.3. CAR-T Cell Therapies and Affiliated Research Landscape

10. EMERGING TECHNOLOGIES

  • 10.1. Chapter Overview
  • 10.2. Genome Editing Technologies
    • 10.2.1. Applications of Genome Editing Technologies
    • 10.2.2. Emerging Technology Platforms for CAR-T Cell Therapy Development and Production
      • 10.2.2.1. CRISPR / Cas9 System
        • 10.2.2.1.1. Key Components and Function
        • 10.2.2.1.2. Mechanism of Action
        • 10.2.2.1.3. Targeting Efficiency and Challenges
        • 10.2.2.1.4. Next-GEN CRISPR Technology
        • 10.2.2.1.5. Technology Providers
          • 10.2.2.1.5.1. Editas Medicine
          • 10.2.2.1.5.2. Intellia Therapeutics
          • 10.2.2.1.5.3. CRISPR Therapeutics
          • 10.2.2.1.5.4. Beam Therapeutics
          • 10.2.2.1.5.5. Gracell Biotechnologies
      • 10.2.2.2. TALENs
        • 10.2.2.2.1. Key Components and Function
        • 10.2.2.2.2. Mechanism of Action
        • 10.2.2.2.3. Advantages and Challenges
        • 10.2.2.2.4. Technology Providers
          • 10.2.2.2.4.1. Cellectis
          • 10.2.2.2.4.2. Editas Medicine
      • 10.2.2.3. megaTAL
        • 10.2.2.3.1. Technology Providers
          • 10.2.2.3.1.1. bluebird bio
      • 10.2.2.4. Zinc Finger Nuclease
        • 10.2.2.4.1. Technology Providers
          • 10.2.2.4.1.1. Sangamo Therapeutics
    • 10.2.3. Competitive Analysis: Gene Editing Platforms
  • 10.3. Designing CAR-T Cell Therapies with Improved Characteristics
    • 10.3.1. Technologies for Targeting Multiple Cancers
      • 10.3.1.1. Antibody Coupled T-Cell Receptor
        • 10.3.1.1.1. Unum Therapeutics
      • 10.3.1.2. NKR-T Platform
        • 10.3.1.2.1. Celyad
        • 10.3.1.2.2. Glycostem
    • 10.3.2. Technologies for Improved Safety
      • 10.3.2.1. Armored CAR and EGFRt Technology
        • 10.3.2.1.1. Juno Therapeutics
      • 10.3.2.2. RheoSwitch Therapeutic System
        • 10.3.2.2.1. Intrexon
      • 10.3.2.3. Inducible Caspase 9 Safety Switch
        • 10.3.2.3.1. Bellicum Pharmaceuticals
          • 10.3.2.3.1.1. CaspaCIDe Technology
          • 10.3.2.3.1.2. CIDeCAR Technology
          • 10.3.2.3.1.3. GoCAR-T Technology
      • 10.3.2.3. On-Off Switch, Multiple Companies
        • 10.3.2.3.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
        • 10.3.2.3.2. On-Off Switch (Theravectys)
      • 10.3.2.4. Other Technologies to Improve CAR-T Safety
    • 10.3.3. Allogeneic Technologies
      • 10.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
      • 10.3.3.2. Allogeneic Platform (Celyad)
      • 10.3.3.3. Allogeneic Platform (Cellectis)

11. CASE STUDY: CELL THERAPY MANUFACTURING

  • 11.1. Chapter Overview
  • 11.2. An Overview to Cell Therapy Manufacturing
  • 11.3. Cell Therapy Manufacturing Models
    • 11.3.1. Centralized Manufacturing Model
    • 11.3.2. Decentralized Manufacturing Model
  • 11.4. Scalability of Cell Therapy Manufacturing Processes
    • 11.4.1. Scale-Up
    • 11.4.2. Scale-out
  • 11.5. Types of Cell Therapy Manufacturers
  • 11.6. Key Challenges Related to Manufacturing Cell Therapies
  • 11.7. Important Factors for Cell Therapy Manufacturing
    • 11.7.1. Characterization
    • 11.7.2. Cost of Goods
  • 11.8. Automation of Cell Therapy Manufacturing Processes
  • 11.9. Cell Therapy Manufacturing Supply Chain
  • 11.10. Companies with In-House Capabilities
  • 11.11. Contract Manufacturers
  • 11.12. Regulatory Landscape

12. COST PRICE ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Factors Contributing to the High Price of Cell / Gene Therapies
  • 12.3. Pricing Models for CAR-T Cell Therapies
    • 12.3.1. Based on Associated Costs
    • 12.3.2. Based on Availability of Competing Products
    • 12.3.3. Based on Patient Segment
    • 12.3.4. Based on the Opinions of Industry Experts
  • 12.4. Reimbursement-related Considerations for CAR-T Cell Therapies
    • 12.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Limitations
  • 13.3. Key Assumptions and Forecast Methodology
  • 13.4. Overall CAR-T Cell Therapy Market, 2019-2030
    • 13.4.1. CAR-T Cell Therapy Market: Distribution by Target Indication
    • 13.4.2. CAR-T Cell Therapy Market: Distribution by Target Antigen
    • 13.4.3. CAR-T Cell Therapy Market: Distribution by Key Players
    • 13.4.4. CAR-T Cell Therapy Market: Distribution by Geography
    • 13.4.5. Product Wise Sales Forecast
      • 13.4.5.1. KYMRIAH® (Novartis)
        • 13.4.5.1.1. Target Patient Population
        • 13.4.5.1.2. Sales Forecast (USD Million)
        • 13.4.5.1.3. Net Present Value
        • 13.4.5.1.4. Value Creation Analysis
      • 13.4.5.2. YESCARTA® (Gilead Sciences)
        • 13.4.5.2.1. Target Patient Population
        • 13.4.5.2.2. Sales Forecast (USD Million)
        • 13.4.5.2.3. Net Present Value (USD Million)
        • 13.4.5.2.4. Value Creation Analysis
      • 13.4.5.3. bb2121 (bluebird bio / Celgene)
        • 13.4.5.3.1. Target Patient Population
        • 13.4.5.3.2. Sales Forecast (USD Million)
        • 13.4.5.3.3. Net Present Value (USD Million)
        • 13.4.5.3.4. Value Creation Analysis
      • 13.4.5.4. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
        • 13.4.5.4.1. Target Patient Population
        • 13.4.5.4.2. Sales Forecast (USD Million)
        • 13.4.5.4.3. Net Present Value (USD Million)
        • 13.4.5.4.4. Value Creation Analysis
      • 13.4.5.5. MB-CART19.1 (Miltenyi Biotec)
        • 13.4.5.5.1. Target Patient Population
        • 13.4.5.5.2. Sales Forecast (USD Million)
        • 13.4.5.5.3. Net Present Value (USD Million)
        • 13.4.5.5.4. Value Creation Analysis
      • 13.4.5.6. CD19 CAR-T (Sinobioway Cell Therapy)
        • 13.4.5.6.1. Target Patient Population
        • 13.4.5.6.2. Sales Forecast (USD Million)
        • 13.4.5.6.3. Net Present Value (USD Million)
        • 13.4.5.6.4. Value Creation Analysis
      • 13.4.5.7. JCAR017 (Juno Therapeutics / Celgene / Wuxi AppTec)
        • 13.4.5.7.1. Target Patient Population
        • 13.4.5.7.2. Sales Forecast (USD Million)
        • 13.4.5.7.3. Net Present Value (USD Million)
        • 13.4.5.7.4. Value Creation Analysis
      • 13.4.5.8. AUTO2 (Autolus)
        • 13.4.5.8.1. Target Patient Population
        • 13.4.5.8.2. Sales Forecast (USD Million)
        • 13.4.5.8.3. Net Present Value (USD Million)
        • 13.4.5.8.4. Value Creation Analysis
      • 13.4.5.9. AUTO3 (Autolus)
        • 13.4.5.9.1. Target Patient Population
        • 13.4.5.9.2. Sales Forecast (USD Million)
        • 13.4.5.9.3. Net Present Value (USD Million)
        • 13.4.5.9.4. Value Creation Analysis
      • 13.4.5.10. GPC3 CAR-T (Shanghai GeneChem)
        • 13.4.5.10.1. Target Patient Population
        • 13.4.5.10.2. Sales Forecast (USD Million)
        • 13.4.5.10.3. Net Present Value (USD Million)
        • 13.4.5.10.4. Value Creation Analysis
      • 13.4.5.11. BCMA CAR-T (The Pregene ShenZhen Biotechnology)
        • 13.4.5.11.1. Target Patient Population
        • 13.4.5.11.2. Sales Forecast (USD Million)
        • 13.4.5.11.3. Net Present Value (USD Million)
        • 13.4.5.11.4. Value Creation Analysis
      • 13.4.5.12. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
        • 13.4.5.12.1. Target Patient Population
        • 13.4.5.12.2. Sales Forecast (USD Million)
        • 13.4.5.12.3. Net Present Value (USD Million)
        • 13.4.5.12.4. Value Creation Analysis
      • 13.4.5.13. CD19 CAR-T (Shanghai Bioray Laboratory)
        • 13.4.5.13.1. Target Patient Population
        • 13.4.5.13.2. Sales Forecast (USD Million)
        • 13.4.5.13.3. Net Present Value (USD Million)
        • 13.4.5.13.4. Value Creation Analysis
      • 13.4.5.14. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
        • 13.4.5.14.1. Target Patient Population
        • 13.4.5.14.2. Sales Forecast (USD Million)
        • 13.4.5.14.3. Net Present Value (USD Million)
        • 13.4.5.14.4. Value Creation Analysis
      • 13.4.5.15. PCAR-019 (PersonGen BioTherapeutics)
        • 13.4.5.15.1. Target Patient Population
        • 13.4.5.15.2. Sales Forecast (USD Million)
        • 13.4.5.15.3. Net Present Value (USD Million)
        • 13.4.5.15.4. Value Creation Analysis
      • 13.4.5.16. TBI-1501 (Takara Bio)
        • 13.4.5.16.1. Target Patient Population
        • 13.4.5.16.2. Sales Forecast (USD Million)
        • 13.4.5.16.3. Net Present Value (USD Million)
        • 13.4.5.16.4. Value Creation Analysis
      • 13.4.5.17. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology)
        • 13.4.5.17.1. Target Population
        • 13.4.5.17.2. Sales Forecast (USD Million)
        • 13.4.5.17.3. Net Present Value (USD Million)
        • 13.4.5.17.4. Value Creation Analysis
      • 13.4.5.18. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
        • 13.4.5.18.1. Target Patient Population
        • 13.4.5.18.2. Sales Forecast (USD Million)
        • 13.4.5.18.3. Net Present Value (USD Million)
        • 13.4.5.18.4. Value Creation Analysis
      • 13.4.5.19. BinD19 (Shenzhen BinDeBio)
        • 13.4.5.19.1. Target Patient Population
        • 13.4.5.19.2. Sales Forecast (USD Million)
        • 13.4.5.19.3. Net Present Value (USD Million)
        • 13.4.5.19.4. Value Creation Analysis
      • 13.4.5.20. CARCIK-CD19 (Formula Pharmaceuticals)
        • 13.4.5.20.1. Target Patient Population
        • 13.4.5.20.2. Sales Forecast (USD Million)
        • 13.4.5.20.3. Net Present Value (USD Million)
        • 13.4.5.20.4. Value Creation Analysis
      • 13.4.5.21. EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
        • 13.4.5.21.1. Target Patient Population
        • 13.4.5.21.2. Sales Forecast (USD Million)
        • 13.4.5.21.3. Net Present Value (USD Million)
        • 13.4.5.21.4. Value Creation Analysis
      • 13.4.5.22. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
        • 13.4.5.22.1. Target Patient Population
        • 13.4.5.22.2. Sales Forecast (USD Million)
        • 13.4.5.22.3. Net Present Value (USD Million)
        • 13.4.5.22.4. Value Creation Analysis

14. PROMOTIONAL ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Channels Used for Promotional Campaigns
  • 14.3. Summary of Product Website Analysis
  • 14.4. Summary of Patient Support Services and Informative Downloads
  • 14.5. KYMRIAH®: Promotional Analysis
    • 14.5.1. Drug Overview
    • 14.5.2. Product Website Analysis
      • 14.5.2.1. Messages for Healthcare Professionals
      • 14.5.2.2. Messages for Patients
    • 14.5.3. Patient Support Services and Informative Downloads
    • 14.5.4. Other Promotional Activities
      • 14.5.4.1. Presence in Conferences
    • 14.6. YESCARTA®: Promotional Analysis
    • 14.6.1. Drug Overview
    • 14.6.2. Product Website Analysis
      • 14.6.2.1. Messages for Healthcare Professionals
      • 14.6.2.3. Messages for Patients
    • 14.6.3. Patient Support Services and Informative Downloads
    • 14.6.4. Other Promotional Activities
      • 14.6.4.1. Presence in Conferences

15. COMPANY PROFILES

  • 15.1. Chapter Overview
  • 15.2. Autolus
  • 15.3. bluebird bio
  • 15.4. CARsgen Therapeutics
  • 15.5. Celgene
  • 15.6. Cell Medica
  • 15.7. Cellectis
  • 15.8. Cellular Biomedicine Group
  • 15.9. Innovative Cellular Therapeutics
  • 15.10. Kite Pharma (A Gilead Sciences Company)
  • 15.11. Noile-Immune Biotech
  • 15.12. Novartis
  • 15.13. Shanghai GeneChem
  • 15.14. Sinobioway Cell Therapy
  • 15.15. Takara Bio
  • 15.16. ZIOPHARM Oncology

16. CONCLUDING REMARKS

  • 16.1. Chapter Overview
  • 16.2. Key Takeaways

17. EXECUTIVE INSIGHTS

  • 17.1. Chapter Overview
  • 17.2. Cell Therapies
    • 17.2.1. Interview Transcript: Tim Oldham, Chief Executive Officer
  • 17.3. Celyad
    • 17.3.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
  • 17.4. Changhai Hospital
    • 17.4.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
  • 17.5. Glycostem Therapeutics
    • 17.5.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
  • 17.6. Gracell Biotechnologies
    • 17.6.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
  • 17.7. Kite Pharma
    • 17.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
  • 17.8. Theravectys
    • 17.8.1. Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
  • 17.9. TxCell
    • 17.9.1. Interview Transcript: Miguel Forte, Chief Operating Officer
  • 17.10. University of Colorado
    • 17.10.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
  • 17.11. Waisman Biomanufacturing
    • 17.11.1. Interview Transcript: Brian Dattilo, Manager of Business Development

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1. Pillars of Cancer Therapy
  • Figure 3.2. Differences between Active and Passive Immunotherapies
  • Figure 3.3. Differences between Specific and Non-Specific Immunotherapies
  • Figure 3.4. Strategies Employed for the Redirection of T-Cells
  • Figure 3.5. T-Cell Manufacturing: General Procedure
  • Figure 3.6. Historical Development of CAR-T cells
  • Figure 3.7. Structure of Chimeric Antigen Receptor
  • Figure 3.8. Chimeric Antigen Receptors: Structural Variations across Different Generations
  • Figure 3.9. CAR-T Cell Therapies: Development Process
  • Figure 3.10. Challenges Associated with CAR-T Cell Therapies
  • Figure 4.1. Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
  • Figure 4.2. Social Media Analysis: Trending Words / Phrases on Twitter
  • Figure 4.3. Social Media Analysis: Most Popular Drug Candidates on Twitter
  • Figure 4.4. Social Media Analysis: Most Prolific Authors on Twitter
  • Figure 4.5. Average Number of Likes, Re-tweets and Comments Related to CAR-T Cell Therapies
  • Figure 4.6. Social Media Analysis: Most Popular Indications and Target Antigen
  • Figure 5.1. CAR-T Cell Therapies: Analysis by Type of Developer
  • Figure 5.2. CAR-T Cell Therapies: Analysis by Phase of Development
  • Figure 5.3. CAR-T Cell Therapies: Analysis by Target Therapeutic Area
  • Figure 5.4. CAR-T Cell Therapies: Analysis by Popular Target Indications
  • Figure 5.5. CAR-T Cell Therapies: Analysis by Popular Target Antigens
  • Figure 5.6. CAR-T Cell Therapies: Analysis by Source of T-Cells
  • Figure 5.7. CAR-T Cell Therapies: Analysis by Route of Administration
  • Figure 5.8. CAR-T Cell Therapies: Analysis by Patient Segment
  • Figure 5.9. CAR-T Cell Therapies: Analysis by Type of Therapy
  • Figure 5.10. CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
  • Figure 5.11. CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
  • Figure 5.12. CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
  • Figure 5.13. CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
  • Figure 6.1. CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
  • Figure 6.2. CAR-T Cell Therapies: Popular Targets in Solid Tumor
  • Figure 6.3. CAR-T Cell Therapies: Geographical Distribution of Key Opinion Leaders
  • Figure 6.4. CAR-T Cell Therapies: Prominent Key Opinion Leaders
  • Figure 6.5. CAR-Construction: Analysis by Generation of CAR-T Therapies
  • Figure 6.6. CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
  • Figure 6.7. CAR-Construction: Analysis by Type of Vector
  • Figure 6.8. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
  • Figure 7.1. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
  • Figure 7.2. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2016-2019)
  • Figure 8.1. Manufacturing of CD19 CAR-T Cells: Process Comparison
  • Figure 9.1. Leukemia: Classification
  • Figure 9.2. Leukemia: Global Epidemiological Distribution
  • Figure 9.3. Lymphoma: Global Epidemiological Distribution
  • Figure 9.4. Multiple Myeloma: Global Epidemiological Distribution
  • Figure 9.5. Melanoma: Global Epidemiological Distribution
  • Figure 9.6. Lung Cancers: Classification
  • Figure 9.7. Lung Cancer: Global Epidemiological Distribution
  • Figure 9.8. Pancreatic Cancer: Global Epidemiological Distribution
  • Figure 9.9. Liver Cancer: Global Epidemiological Distribution
  • Figure 9.10. Breast Cancer: Global Epidemiological Distribution
  • Figure 9.11. Ovarian Cancer: Global Epidemiological Distribution
  • Figure 9.12. Bladder Cancer: Global Epidemiological Distribution
  • Figure 9.13. Kidney Cancer: Global Epidemiological Distribution
  • Figure 10.1. Genome Editing Technologies: Applications
  • Figure 10.2. Genome Editing: Emerging Technology Platforms Used in CAR-T Cell Therapies
  • Figure 10.3. Competitiveness Analysis: Gene Editing Platforms
  • Figure 10.4. CAR-T Cell Therapies: Key Technologies to Enhance Features / Characteristics
  • Figure 10.5. Cellectis: Properties of Enhanced T-Cell Platform
  • Figure 10.6. Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
  • Figure 11.1. Steps for Manufacturing Cell Therapies
  • Figure 11.2. Centralized Manufacturing: Process Model
  • Figure 11.3. Decentralized Manufacturing: Process Model
  • Figure 11.4. Cell Therapy Manufacturing: Types of Manufacturers
  • Figure 11.5. Cell Therapy: Challenges and Drivers
  • Figure 11.6. Cell Therapies: Potency as Critical Quality Attribute
  • Figure 11.7. Cell Therapy Manufacturing: Supply Chain Model
  • Figure 11.8. Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
  • Figure 12.1. Targeted Therapies: Pricing Model Based on Patient Segment
  • Figure 13.1. Overall CAR-T Cell Therapies Market, 2019-2030 (USD Billion)
  • Figure 13.2. CAR-T Cell Therapy Market: Distribution by Target Indication(s) (USD Billion)
  • Figure 13.3. CAR-T Cell Therapy Market: Distribution by Target Antigen(s) (USD Billion)
  • Figure 13.4. CAR-T Cell Therapy Market: Key Players (USD Billion)
  • Figure 13.5. CAR-T Cell Therapy Market: Distribution by Geography (USD Billion)
  • Figure 13.6. KYMRIAH® (Novartis): Current Status of Development
  • Figure 13.7. KYMRIAH® (Novartis) Sales Forecast, till 2030 (USD Million)
  • Figure 13.8. YESCARTA® (Gilead Sciences): Current Status of Development
  • Figure 13.9. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
  • Figure 13.10. bb2121 (bluebird bio / Celgene): Current Status of Development
  • Figure 13.11. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030 (USD Million)
  • Figure 13.12. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen): Current Status of Development
  • Figure 13.13. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030 (USD Million)
  • Figure 13.14. MB-CART19.1 (Miltenyi Biotec): Current Status of Development
  • Figure 13.15. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
  • Figure 13.16. CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
  • Figure 13.17. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
  • Figure 13.18. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Current Status of Development
  • Figure 13.19. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030 (USD Million)
  • Figure 13.20. AUTO2 (Autolus): Current Status of Development
  • Figure 13.21. AUTO2 (Autolus) Sales Forecast, till 2030 (USD Million)
  • Figure 13.22. AUTO3 (Autolus): Current Status of Development
  • Figure 13.23. AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
  • Figure 13.24. GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
  • Figure 13.25. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
  • Figure 13.26. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
  • Figure 13.27. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
  • Figure 13.28. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
  • Figure 13.29. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
  • Figure 13.30. CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
  • Figure 13.31. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
  • Figure 13.32. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
  • Figure 13.33. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, till 2030 (USD Million)
  • Figure 13.36. PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
  • Figure 13.37. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
  • Figure 13.38. TBI-1501 (Takara Bio): Current Status of Development
  • Figure 13.39. TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
  • Figure 13.40. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology): Current Status of Development
  • Figure 13.41. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 13.42. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
  • Figure 13.43. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
  • Figure 13.44. BinD19 (Shenzhen BinDeBio): Current Status of Development
  • Figure 13.45. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
  • Figure 13.46. CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
  • Figure 13.47. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
  • Figure 13.48. EGFR CART (The Beijing Pregene Science and Technology): Current Status of Development
  • Figure 13.49. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 13.50. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Current Status of Development
  • Figure 13.51. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
  • Figure 14.1. Channels Used for Promotional Campaigns
  • Figure 14.2. Promotional / Marketing Strategy: Product Website Analysis
  • Figure 14.3. Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
  • Figure 14.4. Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
  • Figure 14.5. Product Website Analysis: KYMRIAH®, Messages for Patients
  • Figure 14.6. Product Website Analysis: KYMRIAH®, Patient Support Program
  • Figure 14.7. KYMRIAH®, Presence in Conferences
  • Figure 14.8. Product Website Analysis: YESCARTA®, Messages for Healthcare Professionals
  • Figure 14.9. Product Website Analysis: YESCARTA®, Messages for Patients
  • Figure 14.10. Product Website Analysis: YESCARTA®, Kite Konnect
  • Figure 14.11. Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events / Products Complaints and Requesting Medical Information
  • Figure 14.12. YESCARTA®, Presence in Conferences
  • Figure 16.1. CAR-T Cell Therapy Market Landscape: Industry Participants
  • Figure 16.2. CAR-T Cell Therapy Market Landscape: Non-Industry Participants
  • Figure 16.3. CAR-T Cell Therapy Market Forecast, 2019, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List of Tables

  • Table 3.1. Types of Immunotherapies and Affiliated Mechanisms of Action
  • Table 3.2. FDA Approved Antibody based Cancer Therapeutics
  • Table 3.5. Key Characteristics of CAR-T Cells
  • Table 3.6. Comparison of First and Second-Generation CAR-Ts
  • Table 3.7. CD19 CAR-T Cells: Preclinical Results
  • Table 3.8. Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
  • Table 5.1. CAR-T Cell Therapies: Clinical Pipeline
  • Table 5.2. CAR-T Cell Therapies: Preclinical Pipeline
  • Table 6.1. CD19 CAR-T Cell Therapies: Competitive Landscape
  • Table 6.2. CD19 CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.3. BCMA CAR-T Cell Therapies: Competitive Landscape
  • Table 6.4. BCMA CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.5. Meso CAR-T Cell Therapies: Competitive Landscape
  • Table 6.6. Meso CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.7. GD2 CAR-T Cell Therapies: Competitive Landscape
  • Table 6.8. GD2 CAR-T Cell Therapies: Clinical Outcomes
  • Table 6.9. CAR-T Cell Therapies: Principle Investigators
  • Table 6.10. CAR-T Therapies: Information on Constructs of Clinical Candidates
  • Table 7.1. CAR-T Cell Therapies: List of Clinical Trials
  • Table 7.2. Advanced Phase CAR-T Cell Therapies in China
  • Table 8.1. KYMRIAH®: Clinical Studies
  • Table 8.2. KYMRIAH®: Clinical Trial Endpoints (ALL)
  • Table 8.3. KYMRIAH®: Clinical Trial Endpoints (CLL / MM / NHL / FL)
  • Table 8.4. YESCARTA®: Clinical Studies
  • Table 8.5. YESCARTA®: Clinical Trial Endpoints
  • Table 8.6. JCAR Series: Molecules in Clinical Development
  • Table 8.7. JCAR: CAR-T Design
  • Table 8.8. JCAR014: Clinical Studies
  • Table 8.9. JCAR017: Clinical Studies
  • Table 8.10. JCAR018: Clinical Studies
  • Table 8.11. JCAR020: Clinical Studies
  • Table 8.12. JCAR023: Clinical Studies
  • Table 8.13. JCAR024: Clinical Studies
  • Table 8.14. JCARH125: Clinical Studies
  • Table 8.15. JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
  • Table 8.16. JCAR Series: Clinical Trial Endpoints (Phase I)
  • Table 8.17. JCAR: Dosage Regimen
  • Table 8.18. bb2121: Clinical Studies
  • Table 8.19. bb2121: Clinical Trial Endpoints
  • Table 8.20. LCAR-B38M CAR-T: Clinical Studies
  • Table 8.21. LCAR-B38M CAR-T: Clinical Trial Endpoints
  • Table 8.22. Takara Bio's CD19 CAR-T: Clinical Studies
  • Table 8.23. Takara Bio's CD19 CAR-T: Clinical Trial Endpoints
  • Table 8.24. TBI-1501: Dosage Regimen
  • Table 8.25. AUTO2: Clinical Studies
  • Table 8.26. AUTO3: Clinical Studies
  • Table 8.27. Autolus's Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
  • Table 8.28. Sinobioway Cell Therapy's CD19 CAR-T Therapy: Clinical Studies
  • Table 8.29. Sinobioway Cell Therapy's EPCAM CAR-T Therapy: Clinical Studies
  • Table 8.30. Sinobioway Cell Therapy's Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
  • Table 8.31. Phase I/II or Phase II CAR-T Cell Therapies from the Industry Players
  • Table 9.1. Comparison of Hodgkin's and Non-Hodgkin's Lymphoma
  • Table 9.2. Leukemia: List of Marketed Targeted Therapeutics
  • Table 9.3. Lymphoma: List of Marketed Targeted Therapeutics
  • Table 9.4. CAR-T Cell Therapies: Targets under Investigation for Leukemia
  • Table 9.5. CAR-T Cell Therapies: Targets under Investigation for Lymphoma
  • Table 9.6. Multiple Myeloma: List of Marketed Targeted Therapeutics
  • Table 9.7. CAR-T Cell Therapies: Targets under Investigation for Multiple Myeloma
  • Table 9.8. Melanoma: List of Marketed Targeted Therapeutics
  • Table 9.9. Lung Cancer: List of Marketed Targeted Therapeutics
  • Table 9.10. CAR-T Cell Therapies: Targets under Investigation for Lung Cancer
  • Table 9.11. Pancreatic Cancer: List of Marketed Targeted Therapeutics
  • Table 9.12. CAR-T Cell Therapies: Targets under Investigation for Pancreatic Cancer
  • Table 9.13. Liver Cancer: List of Marketed Targeted Therapeutics,
  • Table 9.14. CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
  • Table 9.15. Breast Cancer: List of Marketed Targeted Therapeutics
  • Table 9.16. CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
  • Table 9.17. Ovarian Cancer: List of Marketed Targeted Therapeutics
  • Table 9.18. CAR-T Cell Therapies: Targets under Investigation for Ovarian Cancer
  • Table 9.19. Bladder Cancer: List of Marketed Targeted Therapeutics
  • Table 9.20. Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
  • Table 10.1. Editas Medicine: CRISPR / Cas9 Technology, Research Publications
  • Table 10.2. Editas Medicine: Funding Instances
  • Table 10.3. Editas Medicine: Collaborations
  • Table 10.4. Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
  • Table 10.5. Intellia Therapeutics: Funding Instances
  • Table 10.6. Intellia Therapeutics: Collaborations
  • Table 10.7. CRISPR Therapeutics: CRIPSR / Cas9 Technology, Research Publications
  • Table 10.8. CRISPR Therapeutics: Funding Instances
  • Table 10.9. CRISPR Therapeutics: Collaborations
  • Table 10.10. Beam Therapeutics: Funding Instances
  • Table 10.11. Beam Therapeutics: Collaborations
  • Table 10.12. Gracell Biotechnologies: Funding Instances
  • Table 10.13. Cellectis: Funding Instances
  • Table 10.14. Cellectis: Collaborations
  • Table 10.15. bluebird bio: megaTAL Technology, Research Publications
  • Table 10.16. bluebird bio: Funding Instances
  • Table 10.17. bluebird bio: Collaborations
  • Table 10.18. Sangamo Therapeutics: Funding Instances
  • Table 10.19. Sangamo Therapeutics: Collaborations
  • Table 10.20. Unum Therapeutics: Funding Instances
  • Table 10.21. Unum Therapeutics: Collaborations
  • Table 10.22. Celyad: Funding Instances
  • Table 10.23. Celyad: Collaborations
  • Table 10.24. Glycostem: Funding Instances
  • Table 10.25. Glycostem: Collaborations
  • Table 10.26. Intrexon: Funding Instances
  • Table 10.27. Intrexon: Collaborations
  • Table 10.28. Bellicum Pharmaceuticals: Key Switch Technologies
  • Table 10.29. Bellicum Pharmaceuticals: Switch Technologies, Research Publications
  • Table 10.30. Bellicum Pharmaceuticals: Funding Instances
  • Table 10.31. Bellicum Pharmaceuticals: Collaborations
  • Table 10.32. Theravectys: Funding Instances
  • Table 10.33. Technologies For CAR-T Safety Enhancement
  • Table 10.34. Formula Pharmaceuticals: Collaborations
  • Table 11.1. Assessment Strategies for Different Manufacturing Processes
  • Table 11.2. Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 11.3. Cell Therapy Manufacturing: Companies with In-house Capabilities
  • Table 11.4. Cell Therapy Manufacturing: Contract Manufacturers
  • Table 12.1. Price of Marketed Gene / Cell Therapies
  • Table 12.2. Price of Marketed Targeted Drugs
  • Table 12.3. CAR-T Cell Therapies: Expert Opinions on Pricing
  • Table 12.4. CAR-T Cell Therapies: Reimbursement Landscape
  • Table 13.1. CAR-T Cell Therapies: List of Forecasted Molecules
  • Table 13.2. KYMRIAH® (Novartis): Net Present Value (USD Million)
  • Table 13.3. KYMRIAH® (Novartis): Value Creation Analysis (USD Million)
  • Table 13.4. YESCARTA® (Gilead Sciences): Net Present Value (USD Million)
  • Table 13.5. YESCARTA® (Gilead Sciences): Value Creation Analysis (USD Million)
  • Table 13.6. bb2121 (bluebird bio / Celgene): Net Present Value (USD Million)
  • Table 13.7. bb2121 (bluebird bio / Celgene): Value Creation Analysis (USD Million)
  • Table 13.8. LCAR-B38M (Nanjing Legend Biotech / Janssen): Net Present Value (USD Million)
  • Table 13.9. LCAR-B38M (Nanjing Legend Biotech / Janssen): Value Creation Analysis (USD Million)
  • Table 13.10. MB-CART19.1 (Miltenyi Biotec): Net Present Value (USD Million)
  • Table 13.11. MB-CART19.1 (Miltenyi Biotec): Value Creation Analysis (USD Million)
  • Table 13.12. CD19 CAR-T (Sinobioway Cell Therapy): Net Present Value (USD Million)
  • Table 13.13. CD19 CAR-T (Sinobioway Cell Therapy): Value Creation Analysis (USD Million)
  • Table 13.14. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Net Present Value (USD Million)
  • Table 13.15. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Value Creation Analysis (USD Million)
  • Table 13.16. AUTO2 (Autolus): Net Present Value (USD Million)
  • Table 13.17. AUTO2 (Autolus): Value Creation Analysis (USD Million)
  • Table 13.18. AUTO3 (Autolus): Net Present Value (USD Million)
  • Table 13.19. AUTO3 (Autolus): Value Creation Analysis (USD Million)
  • Table 13.20. GPC3 CAR-T (Shanghai GeneChem): Net Present Value (USD Million)
  • Table 13.21. GPC3 CAR-T (Shanghai GeneChem): Value Creation Analysis (USD Million)
  • Table 13.22. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
  • Table 13.23. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
  • Table 13.24. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
  • Table 13.25. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
  • Table 13.26. CD19 CAR-T (Shanghai Bioray Laboratory): Net Present Value (USD Million)
  • Table 13.27. CD19 CAR-T (Shanghai Bioray Laboratory): Value Creation Analysis (USD Million)
  • Table 13.28. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
  • Table 13.29. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
  • Table 13.30. PCAR-019 (PersonGen BioTherapeutics): Net Present Value (USD Million)
  • Table 13.31. PCAR-019 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
  • Table 13.32. TBI-1501 (Takara Bio): Net Present Value (USD Million)
  • Table 13.33. TBI-1501 (Takara Bio): Value Creation Analysis (USD Million)
  • Table 13.34. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
  • Table 13.35. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
  • Table 13.36. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
  • Table 13.37. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
  • Table 13.38. BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
  • Table 13.39. BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
  • Table 13.40. CARCIK-CD19 (Formula Pharmaceuticals): Net Present Value (USD Million)
  • Table 13.41. CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
  • Table 13.42. EGFR CART (The Beijing Pregene Science and Technology): Net Present Value (USD Million)
  • Table 13.43. EGFR CART (The Beijing Pregene Science and Technology): Value Creation Analysis (USD Million)
  • Table 13.44. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
  • Table 13.45. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
  • Table 14.1. KYMRIAH®: Drug Overview
  • Table 14.2. YESCARTA®: Drug Overview
  • Table 15.1. Autolus: Company Profile
  • Table 15.2. bluebird bio: Company Profile
  • Table 15.3. CARsgen Therapeutics: Company Profile
  • Table 15.4. Celgene: Company Profile
  • Table 15.5. Cell Medica: Company Profile
  • Table 15.6. Cellectis: Company Profile
  • Table 15.7. Cellular Biomedicine Group: Company Profile
  • Table 15.8. Innovative Cellular Therapeutics: Company Profile
  • Table 15.9. Kite Pharma: Company Profile
  • Table 15.10. Noile-Immune Biotech: Company Profile
  • Table 15.11. Novartis: Company Profile
  • Table 15.12. Shanghai Genechem: Company Profile
  • Table 15.13. Sinobioway Cell Therapy: Company Profile
  • Table 15.14. Takara Bio: Company Profile
  • Table 15.15. ZIOPHARM Oncology: Company Profile
  • Table 18.1. CAR-T Cell Therapies: Analysis by Type of Developer
  • Table 18.2. CAR-T Cell Therapies: Analysis by Phase of Development
  • Table 18.3. CAR-T Cell Therapies: Analysis by Target Therapeutic Area
  • Table 18.4. CAR-T Cell Therapies: Analysis by Popular Target Indications
  • Table 19.5. CAR-T Cell Therapies: Analysis by Target Antigen
  • Table 18.6. CAR-T Cell Therapies: Analysis by Source of T-Cells
  • Table 18.7. CAR-T Cell Therapies: Analysis by Route of Administration
  • Table 18.8. CAR-T Cell Therapies: Analysis by Patient Segment
  • Table 18.9. CAR-T Cell Therapies: Analysis by Type of Therapy
  • Table 18.10. CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
  • Table 18.11. CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
  • Table 18.12. CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
  • Table 18.13. CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
  • Table 18.14. CAR-T Cell Therapies: Popular Targets in Hematological Cancer
  • Table 18.15. CAR-T Cell Therapies: Popular Targets in Solid Tumor
  • Table 18.16. CAR-Construction: Analysis by Generation of CAR-T Therapies
  • Table 18.17. CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
  • Table 18.18. CAR-Construction: Analysis by Type of Vector
  • Table 18.19. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
  • Table 18.20. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
  • Table 18.21. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
  • Table 18.22. Overall CAR-T Cell Therapies Market, 2019-2030: Conservative Scenario (USD Billion)
  • Table 18.23. Overall CAR-T Cell Therapies Market, 2019-2030: Base Scenario (USD Billion)
  • Table 18.24. Overall CAR-T Cell Therapies Market, 2019-2030: Optimistic Scenario (USD Billion)
  • Table 18.25. CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Billion)
  • Table 18.26. CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Billion)
  • Table 18.27. CAR-T Cell Therapies Market: Key Players (USD Billion)
  • Table 18.28. CAR-T Cell Therapies Market: Distribution by Geography (USD Billion)
  • Table 18.29. KYMRIAH® (Novartis) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.30. KYMRIAH® (Novartis) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.31. KYMRIAH® (Novartis) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.32. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.33. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.34. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.35. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.36. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.37. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.38. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.39. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.40. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.41. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.42. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.43. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.44. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.45. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.46. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.47. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.48. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.49. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.50. AUTO2 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.51. AUTO2 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.52. AUTO2 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.53. AUTO3 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.54. AUTO3 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.55. AUTO3 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.56. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.57. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.58. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.59. BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.60. BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.61. BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.62. CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.63. CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.64. CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.65. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.66. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.67. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.68. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.69. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.70. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.71. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.72. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.73. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.74. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.75. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.76. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.77. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.78. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.79. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.80. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.81. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.82. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.83. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.84. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.85. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.86. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.87. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.88. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.89. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.90. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.91. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.92. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
  • Table 18.93. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
  • Table 18.94. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
  • Table 18.95. CAR-T Cell Therapy Market Forecast, 2019, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1.3P Biopharmaceuticals
  • 2.Abramson Cancer Center
  • 3.AbCheck
  • 4.AbClon
  • 5.Abingworth
  • 6.AbVitro
  • 7.ACEA Biosciences
  • 8.Acerta Pharma
  • 9.Acorn Pacific Ventures
  • 10.Adage Capital Management
  • 11.Adaptimmune Therapeutics
  • 12.Adicet Bio
  • 13.Adimab
  • 14.Advanced BioScience Laboratories
  • 15.Advent Bioservices
  • 16.Adverum Biotechnologies
  • 17.Aeon Therapeutics
  • 18.Affiliated Hospital to Academy of Military Medical Sciences
  • 19.Agent Capital
  • 20.AgenTus Therapeutics
  • 21.Agreen Biotech
  • 22.Alberta Cell Therapy Manufacturing
  • 23.Allele Biotechnology and Pharmaceuticals
  • 24.Aokai Biotech
  • 25.Akron Biotech
  • 26.AK (Suzhou) Biomedical
  • 27.Allergan
  • 28.Allife Medical Science and Technology
  • 29.Allogene Therapeutics
  • 30.Alpine Immune Sciences
  • 31.Amsterdam BioTherapeutics Unit
  • 32.Amgen
  • 33.Andalusian Initiative for Advanced Therapies
  • 34.Anhui Provincial Hospital
  • 35.Antagene
  • 36.Anterogen
  • 37.apceth Biopharma
  • 38.Aquilo Capital Management
  • 39.ARBELE
  • 40.Argos Therapeutics
  • 41.ARIAD Pharmaceuticals
  • 42.Arix Bioscience
  • 43.Asahi Glass Company
  • 44.Asterias Biotherapeutics
  • 45.Astellas Pharma
  • 46.AstraZeneca
  • 47.Asymptote
  • 48.Atlantic Bio GMP
  • 49.Atossa Genetics
  • 50.Atreca
  • 51.Aurora Biopharma
  • 52.Autolus
  • 53.Avacta
  • 54.Batavia Biosciences
  • 55.Bavarian Nordic
  • 56.Baxalta
  • 57.Bayer
  • 58.Baylor College of Medicine
  • 59.Be The Match BioTherapies
  • 60.Beijing Biohealthcare Biotechnology
  • 61.Beijing Doing Biomedical
  • 62.Beijing Immunochina Medical Science and Technology
  • 63.Beijing Mario Biotechnology
  • 64.Beijing Sanwater Biological Technology
  • 65.Beijing You'an Hospital
  • 66.Bellicum Pharmaceuticals
  • 67.Beth Israel Deaconess Medical Center
  • 68.BioAtla
  • 69.Bioceltech Therapeutics
  • 70.Bio Elpida
  • 71.Biogen
  • 72.BioLife Solutions
  • 73.Bioinova
  • 74.Biomedical Catalyst
  • 75.BioNTech
  • 76.bluebird bio
  • 77.Boehringer Ingelheim
  • 78.Bone Therapeutics
  • 79.Boston Children's Hospital
  • 80.Brammer Bio
  • 81.Bristol-Myers Squibb
  • 82.Cabaret Biotech
  • 83.California Institute for Regenerative Medicine
  • 84.Canaan Partners
  • 85.Cancer Research UK
  • 86.Cancer Prevention Research Institute of Texas
  • 87.Cantor Fitzgerald
  • 88.Captain T Cell
  • 89.Capricor Therapeutics
  • 90.Cardiff University
  • 91.Cartherics
  • 92.Caribou Biosciences
  • 93.Carina Biotech
  • 94.CARsgen Therapeutics
  • 95.Cartesian Therapeutics
  • 96.Cartherics
  • 97.Casebia Therapeutics
  • 98.Cell Biotech
  • 99.Celdara Medical
  • 100.Cellectis
  • 101.Cell Design Labs
  • 102.Celgene
  • 103.Cell and Gene Therapy Catapult
  • 104.Cellin Technologies
  • 105.Cell Medica
  • 106.Cellular Biomedicine Group
  • 107.CELLforCURE
  • 108.Cell Tech Pharmed
  • 109.Cell Therapies
  • 110.Cooperative Research Centre for Cell Therapy Manufacturing
  • 111.Cellular Therapeutics
  • 112.Celyad
  • 113.Center for Cell and Gene Therapy
  • 114.Center for Cell Manufacturing Ireland, National University of Ireland Galway
  • 115.Changhai Hospital
  • 116.CHDI Foundation
  • 117.Chengdu Miaoji Medical Technology
  • 118.Chiesi Farmaceutici
  • 119.China Regenerative Medicine International
  • 120.Children's Hospital of Philadelphia
  • 121.Children's Mercy Hospital
  • 122.Children's Oncology Group
  • 123.Children's Research Institute
  • 124.Chinese Academy of Sciences
  • 125.Chinese PLA General Hospital
  • 126.Christie NHS Foundation Trust
  • 127.Clough Capital Partners
  • 128.City of Hope National Medical Center
  • 129.Cognate BioServices
  • 130.Columbia University
  • 131.Cook MyoSite
  • 132.Copenhagen University Hospital
  • 133.CRISPR Therapeutics
  • 134.Cryoport
  • 135.Cryosite
  • 136.CTI Clinical Trial and Consulting Services
  • 137.CureVac
  • 138.Cystic Fibrosis Foundation Therapeutics
  • 139.CytoLumina Technologies
  • 140.Cytovance Biologics
  • 141.Daiichi Sankyo
  • 142.Dana-Farber Cancer Institute
  • 143.Dangdai International Group
  • 144.Dartmouth College
  • 145.Delenex Therapeutics
  • 146.Dendreon
  • 147.Dongguan People's Hospital
  • 148.Dow AgroSciences
  • 149.Duke Cancer Institute
  • 150.Editas Medicine
  • 151.Eli Lilly
  • 152.Emory Personalized Immunotherapy Core
  • 153.Endocyte
  • 154.ERS Genomics
  • 155.European Commission
  • 156.Eurostars
  • 157.Eutilex
  • 158.Eureka Therapeutics
  • 159.EXUMA Biotechnology
  • 160.F1 BioVentures
  • 161.F1 Oncology
  • 162.Fate Therapeutics
  • 163.Fetolumina Technologies
  • 164.First Affiliated Hospital of Chengdu Medical College
  • 165.First Affiliated Hospital of Harbin Medical University
  • 166.First Affiliated Hospital of Sun Yat-sen University
  • 167.First Affiliated Hospital of Wenzhou Medical University
  • 168.First Affiliated Hospital of Zhejiang University
  • 169.First People's Hospital of Foshan
  • 170.F-Prime Capital
  • 171.Five Prime Therapeutics
  • 172.Fondazione Telethon and Ospedale San Raffaele
  • 173.Foresite Capital
  • 174.Forevertek Biotechnology
  • 175.Formula Pharmaceuticals
  • 176.Fortress Biotech
  • 177.Fosun Pharmaceutical
  • 178.Fred Hutchinson Cancer Research Center
  • 179.Fraunhofer Institute for Cell Therapy and Immunology
  • 180.Friedreich's Ataxia Research Alliance
  • 181.Froceth
  • 182.Fuda Cancer Hospital
  • 183.Fudan University
  • 184.FUJIFILM Cellular Dynamics
  • 185.Fujian Medical University
  • 186.Gamida Cell
  • 187.Gadeta
  • 188.Gene and Cell Therapy Lab
  • 189.GE Healthcare Life Sciences
  • 190.Genentech
  • 191.GenCure
  • 192.Genmab
  • 193.Genus Oncology
  • 194.German Federal Ministry of Education and Research
  • 195.Ghent University Hospital
  • 196.GigaGen
  • 197.Gilead Sciences
  • 198.GlaxoSmithKline
  • 199.Glycostem
  • 200.Gracell Biotechnologies
  • 201.Guangzhou Anjie Biomedical Technology
  • 202.Guangzhou Yiyang Biological Technology
  • 203.Guangzhou Eighth People's Hospital
  • 204.Guangzhou First People's Hospital
  • 205.Guangdong Zhaotai InVivo Biomedicine
  • 206.Guy's and St Thomas' NHS Foundation Trust
  • 207.Hadassah Medical Center
  • 208.Haitong International Securities
  • 209.Hangzhou Cancer Hospital
  • 210.Harbin Medical University
  • 211.Harvard University
  • 212.Hebei Senlang Biotechnology
  • 213.Hebei Yanda Ludaopei Hospital
  • 214.Helix BioPharma
  • 215.Henan Cancer Hospital
  • 216.Henan Hualong Biotechnology
  • 217.Herlev Hospital
  • 218.Histocell
  • 219.Hitachi Chemical Advanced Therapeutics Solutions
  • 220.H. Lee Moffitt Cancer Center and Research Institute
  • 221.Horizon Discovery
  • 222.Horizon Technology Finance
  • 223.Howard Hughes Medical Institute
  • 224.Hrain Biotechnology
  • 225.Human Stem Cells Institute
  • 226.Hunan Yongren Medical Innovation
  • 227.iCarTAB BioMed
  • 228.iCell Gene Therapeutics
  • 229.Icell Kealex Therapeutics
  • 230.ICON
  • 231.Immune Therapeutics
  • 232.Imperial College London
  • 233.Innovate UK
  • 234.Innovative Cellular Therapeutics
  • 235.Innovative Genomins Institute
  • 236.Intellia Therapeutics
  • 237.Intrexon
  • 238.Institut Curie
  • 239.Institut Pasteur
  • 240.Instituto de Salud Carlos III
  • 241.Iowa State University Research Foundation
  • 242.Janssen Biotech
  • 243.Japan Science and Technology Agency
  • 244.Jazz Pharmaceuticals
  • 245.JCR Pharmaceuticals
  • 246.Jiangsu Cancer Hospital
  • 247.JIG Genesis Fountain Healthcare Ventures
  • 248.Johns Hopkins University
  • 249.Jolly Innovation Ventures
  • 250.Jonsson Comprehensive Cancer Center
  • 251.Juno Therapeutics
  • 252.JW Biotechnology
  • 253.KAEDI
  • 254.Kaitai Capital
  • 255.Karolinska University Hospital
  • 256.KBI Biopharma
  • 257.Keio University
  • 258.King's College London
  • 259.Kite Pharma
  • 260.Leucid Bio
  • 261.Lexicon Pharmaceuticals
  • 262.Lonza
  • 263.Loughborough University
  • 264.MabQuest
  • 265.Marino Biotechnology
  • 266.MaSTherCell
  • 267.Massachusetts General Hospital Cancer Center
  • 268.MaxCyte
  • 269.Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • 270.MD Anderson Cancer Center
  • 271.Medarex
  • 272.Medical College of Wisconsin
  • 273.MEDINET
  • 274.MedImmune
  • 275.Medisix Therapeutics
  • 276.Medpost Urgent Care
  • 277.Memorial Sloan Kettering Cancer Center
  • 278.Merck
  • 279.Merck Serono
  • 280.Merlin Nexus
  • 281.Mesoblast
  • 282.Mie University
  • 283.Millennium Pharmaceuticals (acquired by Takeda Oncology)
  • 284.Miller Value Partners
  • 285.Miltenyi Biotec
  • 286.MingJu Therapeutics Shanghai
  • 287.Minerva Biotechnologies
  • 288.Moffitt Cancer Center
  • 289.Molecular and Cellular Therapeutics
  • 290.MolMed
  • 291.Mustang Bio
  • 292.Nanfang Hospital of Southern Medical University
  • 293.Nanjing Children's Hospital
  • 294.Nanjing Legend Biotech
  • 295.NantKwest
  • 296.National Cancer Institute
  • 297.National Heart, Lung, and Blood Institute
  • 298.National Institutes of Health
  • 299.National University of Singapore
  • 300.Navy General Hospital (Beijing)
  • 301.Netherlands Cancer Institute
  • 302.Ningbo Cancer Hospital
  • 303.Nikon CeLL innovation
  • 304.Nohla Therapeutics
  • 305.Noile-Immune Biotech
  • 306.Northland Capital Markets
  • 307.Novadip Biosciences
  • 308.Novartis
  • 309.Obsidian Therapeutics
  • 310.Oncodesign
  • 311.OncoTracker
  • 312.OnCyte
  • 313.Ono Pharmaceutical
  • 314.Onyx Pharmaceuticals
  • 315.Opexa Therapeutics
  • 316.Opus Bio
  • 317.Bambino Gesù Hospital
  • 318.Oxford BioMedica
  • 319.PACT Pharma
  • 320.PCI Services
  • 321.PCT Cell Therapy Services
  • 322.Peking University
  • 323.Pentwater Capital Management
  • 324.PeproMene Bio
  • 325.Peter MacCallum Cancer Centre
  • 326.PersonGen BioTherapeutics (Suzhou)
  • 327.Pfizer
  • 328.PharmaBio
  • 329.PharmaCell
  • 330.Pharmicell
  • 331.Phio Pharmaceuticals
  • 332.Pinze Lifetechnology
  • 333.Pluristem Therapeutics
  • 334.PolyBioCept
  • 335.Poseida Therapeutics
  • 336.Praxis Pharmaceutical
  • 337.Precision BioSciences
  • 338.Precision Genome Engineering
  • 339.Princess Margaret Cancer Centre
  • 340.ProMab Biotechnologies
  • 341.Promethera Biosciences
  • 342.Provia Laboratories
  • 343.Puma Biotechnology
  • 344.PureTech Health
  • 345.RedoxTherapies (acquired by Juno Therapeutics)
  • 346.Redmile Group
  • 347.Relieve Genetics
  • 348.Regeneron Pharmaceuticals
  • 349.Renji Hospital
  • 350.Renmin Hospital of Wuhan University
  • 351.Riyadh Pharma
  • 352.Roche
  • 353.Rockland Immunochemicals
  • 354.Roger Williams Medical Center
  • 355.Roswell Park Comprehensive Cancer Center
  • 356.Royal Adelaide Hospital
  • 357.RXi Pharmaceuticals
  • 358.Sangamo Therapeutics
  • 359.San Raffaele Hospital
  • 360.Scotia Biologics
  • 361.Scottish National Blood Transfusion Service
  • 362.Seattle Genetics
  • 363.Seattle Children's Hospital
  • 364.Second Affiliated Hospital of Guangzhou Medical University
  • 365.Second Military Medical University
  • 366.Servier
  • 367.Shanghai Bioray Laboratory
  • 368.Shanghai Changzheng Hospital
  • 369.Shanghai Cell Therapy Engineering Technology Research Center
  • 370.Shanghai Chest Hospital
  • 371.Shanghai Children's Medical Center
  • 372.Shanghai GeneChem
  • 373.Shanghai General Hospital
  • 374.Shanghai Jiao Tong University School of Medicine
  • 375.Shanghai Longyao Biotechnology
  • 376.Shanghai Sinobioway Sunterra Biotechnology
  • 377.Shanghai Sunway Biotech
  • 378.Shanghai Tongji Hospital
  • 379.Shanghai Unicar-Therapy Bio-medicine Technology
  • 380.Sheba Medical Center
  • 381.Shenzhen BinDeBio
  • 382.Shenzhen Geno-Immune Medical Institute
  • 383.Shenzhen Institute for Innovation and Translational Medicine
  • 384.Shenzhen Second People's Hospital
  • 385.Shire
  • 386.Sibiono GeneTech
  • 387.Sichuan University
  • 388.Sinobioway Cell Therapy
  • 389.Southwest General Health Center
  • 390.Sorrento Therapeutics
  • 391.Spark Therapeutics
  • 392.Stage Cell Therapeutics
  • 393.Stanford University
  • 394.St. George's Hospital
  • 395.Stem Cell Institute
  • 396.St. Jude Children's Research Hospital
  • 397.SOTIO
  • 398.StrideBio
  • 399.Sun Yat-sen University
  • 400.Syncona
  • 401.Tactiva Therapeutics
  • 402.Takeda Pharmaceutical
  • 403.Takara Bio
  • 404.TC BioPharm
  • 405.T-Cell Factory (acquired by Kite Pharma)
  • 406.Tel Aviv Sourasky Medical Center
  • 407.TeneoBio
  • 408.Tesaro (acquired by GSK)
  • 409.Terumo Medical
  • 410.Nanjing Drum Tower Hospital
  • 411.The Beijing Pregene Science and Technology
  • 412.The First Affiliated Hospital of Guangdong Pharmaceutical University
  • 413.The First Affiliated Hospital of Soochow University
  • 414.The First People's Hospital of Yunnan
  • 415.The Pregene (ShenZhen) Biotechnology
  • 416.The Third Affiliated Hospital of Southern Medical University
  • 417.The Ohio State University Comprehensive Cancer Center
  • 418.Theravectys
  • 419.The Research Council of Norway
  • 420.The Second Xiangya Hospital of Central South University
  • 421.The University of Texas
  • 422.The University of Utah
  • 423.Henan University of Traditional Chinese Medicine
  • 424.Thermo Fisher Scientific
  • 425.The Wistar Institute
  • 426.Third Military Medical University
  • 427.Tianjin Medical University Cancer Institute and Hospital
  • 428.Tianjin Mycure Medical Technology
  • 429.TiGenix
  • 430.TILT Biotherapeutics
  • 431.Timmune Biotech
  • 432.TissueGene-C
  • 433.Tmunity Therapeutics
  • 434.TNK Therapeutics
  • 435.Tongji University School of Medicine
  • 436.Touchstone Innovations
  • 437.TrakCel
  • 438.Transgene
  • 439.Transposagen Biopharmaceuticals
  • 440.TxCell (acquired by Sangmo)
  • 441.UNC Lineberger Comprehensive Cancer Center
  • 442.Union Stem Cell & Gene Engineering
  • 443.Universal Cells
  • 444.University College London
  • 445.University Health Network
  • 446.University of Birmingham
  • 447.University of British Columbia
  • 448.University of California
  • 449.University of Florida
  • 450.University Hospital of Basel
  • 451.University of Lausanne
  • 452.University of Manchester
  • 453.University Medical Center Utrecht
  • 454.University of Milano-Bicocca
  • 455.University of Minnesota
  • 456.University of North Carolina
  • 457.University of Oxford
  • 458.University of Pennsylvania
  • 459.University of Rochester
  • 460.University of Zurich
  • 461.Uppsala University
  • 462.Unum Therapeutics
  • 463.Vaccinogen
  • 464.Vecura
  • 465.venBio
  • 466.Vericel
  • 467.Vertex Pharmaceuticals
  • 468.Vical
  • 469.Vineti
  • 470.Waisman Biomanufacturing
  • 471.Washington University
  • 472.Weill Cornell Medical College
  • 473.Wuhan Union Hospital
  • 474.Wuhan Sian Medical Technology
  • 475.WuXi AppTec
  • 476.Xellbiogene
  • 477.Xiangxue Pharmaceutical
  • 478.Xinqiao Hospital
  • 479.Xijing Hospital
  • 480.Xuzhou Medical University
  • 481.Yake Biotechnology
  • 482.Yuanyi Biotechnology
  • 483.Zhejiang Huahai Pharmaceutical
  • 484.Zhejiang University
  • 485.Zhujiang Hospital
  • 486.ZIOPHARM Oncology